HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avon Q2 guidance

This article was originally published in The Rose Sheet

Executive Summary

Beauty sales expected to increase 11%-13% in the second quarter, driven by a double-digit increase in the U.S., direct-seller reports during Sanford Bernstein Strategic Decisions conference June 3. U.S. sales in Q2 are projected to be up 3%, led by beauty and representative growth, Avon adds. Earnings in the second quarter will increase mid-single digits over year-ago period, firm states. Separately, Avon announced June 4 it has hired talent marketing firm Creative Artists Agency to develop brand-building opportunities in entertainment industry to promote new teen cosmetics initiative mark., which bows in August (1"The Rose Sheet" March 31, 2003, p. 3)...

You may also be interested in...



Avon Aiming For $100 Mil. Mark With Teen Initiative In U.S. In 2004

Avon expects its new mark. teen-targeted cosmetics business to generate U.S. sales of $100 mil. in 2004, the brand's first full year of operation, the direct-seller predicted during a meeting with investors March 28

No To Grapefruit Mask? Natural Player Yes To, Inc. Issues Recall Following ‘Chemical Burn’ Reports

Yes To is investigating reports – including posts on leading social media platforms – regarding irritation and redness experienced by children and other users of its Yes To Grapefruit Glow-Boosting Unicorn Paper Mask. In the meantime, the company is recalling the product voluntarily.

Warning Letter Roundup & Recap – 21 January 2020

A maker of low-level LED light-therapy devices was cited by the US FDA for premarket, quality systems and Medical Device Reporting violations. It's just one of two device-related warning letters released by the agency this week.

UsernamePublicRestriction

Register

RS011256

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel